SLC7A11 and neoplasm: Cobler et al. reported that SLC7A11-specific therapeutics would provide tumor-specific radiosensitivity to γ radiation in breast cancer cells, which allows the use of lower radiation doses in treatments, thus producing fewer side effects than other proposed sensitizers [59].